Martoma, 40, was sentenced in federal court last month by US District Judge Paul Gardephe for his role as the "central figure" in the most lucrative insider trading scheme ever charged involving $275 million in illegal profits and avoided losses.
The appeals court granted Martoma's request to extend his November 10 surrender date until an appellate panel hears and decides on his motion for bail pending appeal.
He was sentenced to nine and five years on charges of conspiracy and two of securities fraud.
Martoma, 40, was ordered by US District Judge Paul Gardephe to surrender by Thursday afternoon, after he lost his bid last week to remain free on bail pending appeal of his conviction.
Mathew Martoma helped SAC reap more than $275 million profit.
Indian-origin Mathew Martoma, convicted for his role in the most lucrative insider trading scheme in US history involving $275 million, will be sentenced in June and could face about 20 years in prison.
Years before he was accused of insider trading, former SAC Capital Advisors portfolio manager Mathew Martoma forged a Harvard transcript, falsified an email, and created a dummy forensic computing company to try to cover his tracks.
The maximum prison sentence he face is 45 years, but Martoma could be given a lesser prison time under federal sentencing guidelines.
Mathew Martoma, a former SAC Capital portfolio manager, faces 20 years in prison for securities fraud and five years for conspiracy
'Serious crimes of this sort cannot be excused merely because he has a family.' P Rajendran/Rediff.com was in the courtroom last week when Mathew Martoma was sentenced to nine years in prison for insider trading.
This is the first time the Stanford Graduate School of Business has revoked a graduate's degree.
Two Indian Americans are at the centre of a case, which resulted in a deal that brought $600 million to the Securities and Exchange Commission, the largest amount it got ever to settle an investigation.
The insider trading is considered one of the most lucrative one involving $276 million.
Mathew Martoma is charged with using non-public informationm, that he received from a doctor on the clinical trial of an Alzheimer's disease drug, to make profits.
Mathew Martoma, 38, was arraigned at Manhattan federal court in New York on Thursday before Judge Paul Gardephe and entered a not guilty plea to one count of conspiracy to commit securities fraud and two counts of securities fraud.
© 2026 Rediff.com - Investor Information - Advertise with us - Disclaimer - Privacy Policy - Sitemap - Feedback - About us - Terms of use - Grievances